NOU: Consultații ONLINE

Dr. Costa Daniel

Psihiatrie

Ontario, C.M.I. Dr. Daniel Costa

Articole publicate si prezentari la intruniri internationale

PUBLICATIONS:

1. Costa, D. et al. Endogenous depression and imipramine levels in the blood. Psychopharmacology 1980; 7:291-294.

2. Costa, D. et al. Breast and other cancer deaths in a mental hospital. Neoplasma 1981; 28:371-378.

3. Costa, D. and Popescu, A. Psychic manifestations in 117 young women of Bucharest after March 4, 1977 earthquake. Revue Roumaine de Medecine - Neurologie et Psychiatrie 1981; 19:45-51. This work includes 24 cases of post-traumatic stress reaction in young women after a 7.2 Richter earthquake.

4. Costa, D. et al. Chlorpromazine-induced decrease of red-cell aggregability. Romanian Journal of Internal Medicine 1981.

5. Costa, D. et al. Clinical and paraclinical aspects of tetany in stuttering. Neurologie et Psychiatrie 1983; 21:277-279.

6. Costa, D. Mianserin in depressed and non-depressed stutterers. Book of Abstracts, 13th Collegium Internationale Neuropsychopharmacologicum Congress, Jerusalem, Israel, 1982.

7. Costa, D. et al. A comparison between efficacy and safety of mianserin and placebo in the treatment of depression secondary to cancer. Clinical Neuropharmacology 1984; 7 (suppl. 1): 352-353. Presented at the 14th Collegium Internationale Neuropsychopharmacologicum Congress, Florence, Italy, 1984.

8. Costa, D. et al. Efficacy and safety of mianserin in the treatment of depression in women with cancer. Acta Psychiatrica Scandinavica 1985; 72:85-92. Abstracted in Digest of Neurology and Psychiatry.

9. Costa, D. et al. Clinical and paraclinical aspects of tetany in stuttering. Activitas Nervosa Superior 1986; 28:156-158.

10. Costa, D. et al. Serum immunoreactive parathormone levels correlate with depression and anxiety in hypocalcemic stutterers. Activitas Nervosa Superior 1986; 28:155-156.

11. Kennedy, S., Costa, D., Parienti, V. and Brown, G.M. Is melatonin a neuroendocrine marker in bulimia? In: Hudson, J. and Pope, H.: Psychobiology of Bulimia. American Psychiatric Press, 1987.

12. Costa, D. Mianserin treatment for depression in cancer patients. Book of Abstracts, 16th European Conference on Psychosomatic Research. Athens, Greece, 1986. Presented at the above-mentioned conference and at Athens Cancer Institute.

13. Kennedy, S.H., Garfinkel, P.E., Parienti, V., Costa, D., Brown, G.M. Changes in melatonin but not cortisol are associated with depression in eating disorder patients. Archives of General Psychiatry, 1989; 46:73-78.

14. Kennedy, S.H., Brown, G.M., Garfinkel, P.E., McVey, G., Costa, D., Parienti, V. Sulphatoxy melatonin - An index of depression in anorexia nervosa and bulimia nervosa. Psychiatry Research 1990; 32:221-227.

15. Costa, D. Antidepressants and the treatment of stuttering. American Journal of Psychiatry, 1992; 149:1281.

16. Costa, D. Antidepressants in the medically ill: Developments in research and clinical usage. Clinical Neuropharmacology, 1992; 15, Supplement 1, Part B, page 142.

17. Costa, D. Psychopharmacologic perspectives in stuttering: A possible role for SSRI’s. Neuropsychopharmacology 1994; 10; No. 3S, Part 1, page 352S.

18. Costa, D., Kroll, R.M. Treatment of stuttering with paroxetine: A case study. Journal of Fluency Disorders. Proceedings of the 1st World Congress on Fluency Disorders, August 8-12, 1994, Munich, Germany. Volume 11, page 511-513.

19. Costa, D., Kroll, R.M. Sertraline in stuttering. Journal of Clinical Psychopharmacology 1995; Volume 15: 443-444.

20. Costa, D. Antidepressants in Clinical Oncology and Speech Pathology. Mendlewicz J, Brunello N, Judd LL (eds): New Therapeutic Indications of Antidepressants. Int. Acad. Biomed. Res. Basel, Karger, 1997, vol 12, pp 130-133.

21. Costa, D. Psychiatric Detection of Exaggeration in Reports of Memory Impairment. Journal of Nervous and Mental Disease 1999; Volume 187: 446-448.

22. Costa D., Kroll R.M. Stuttering: an update for physicians. CMAJ 2000; Volume 162: 1849-55.

SCIENTIFIC PRESENTATIONS:

1. Endogenous depression and imipramine levels in the blood. Collegium Internationale Neuro-Psychopharmacologicum (CINP) Congress, Vienna, 1978.

2. A comparison between the efficacy and safety of mianserin and placebo in the treatment of depression secondary to cancer. Symposium at the CINP Congress in Florence, Italy, 1984.

3. Mianserin treatment for depression in cancer patients. European Conference on Psychosomatic Research, Athens, Greece, 1986.

4. Melatonin and cortisol studies in bulimia. 13th Annual Research Day, University of Toronto, Department of Psychiatry, 1987.

5. Efficacy of mianserin in the treatment of depression in women with cancer. Presented as a member of the faculty at the 13th Annual Course of the American Academy of Psychiatry, Toronto, October 7-10, 1987.

6. Antidepressants in the medically ill. CINP Congress of Nice, France, 1992.

7. Co-chair of the symposium THE PHARMACOLOGIC TREATMENT OF STUTTERING at the CINP Congress of Washington, D.C., 1994. Also presented: Psychopharmacologic perspectives in stuttering: A possible role for SSRI’s.

8. Paroxetine in the treatment of stuttering: A case study. The 1st World Congress of Fluency, Munich, Germany, 1994.

9. Antidepressants in clinical oncology and speech pathology. Presented as invited speaker at the Workshop on NEW THERAPEUTIC INDICATIONS OF ANTIDEPRESSANTS, Bruges, Belgium, March 22-23, 1996. Organized by the International Academy for Biomedical and Drug Research under the patronage of WHO and the European Commission. Published by KARGER.

10. Psychiatric Determination of Feigned Memory Deficit (Feigned Memory Deficit, Mental Status Tests and Diagnosis in Personal Injury Claimants and Litigants With or Without Head Trauma). Presented on June 3, 1998, Room 106, Lower Level, Toronto Convention Centre, at the 1998 American Psychiatric Association Annual Meeting in Toronto, May 30-June 4.

11. The Neuro-pharmacology of Persistent Stuttering. Presented as symposium chair at the July
9-13, 2000 CINP Congress in Brussels, Belgium.

12. Scientific Chair of the 1st International Conference on Symptom, Diagnostic, and Disability
Validity: Improving Patient Outcomes. Markham-Toronto, Ontario, Canada. September 26-29,
2002. Opening and closing remarks. Conference web site: www.icpro.org

13. Antidepressants and the assessment of disability. The 1st International Conference on Symptom,
Diagnostic, and Disability Validity: Improving Patient Outcomes. Markham-Toronto, Ontario,
Canada. September 26-29, 2002.




OTHER ACHIEVEMENTS:

I am cited in the American Psychiatric Press Textbook of Psychiatry, 2003, page 635, for research in depression in the medically ill.

I am also cited in the American Psychiatric Press Textbook of Consultation-Liaison Psychiatry, 1996, pages 813 and 814, for research in depression in the medically ill. In addition, this research is also cited in established textbooks of medicine such as De Vita.

My trial of mianserin in depressed cancer patients published in Acta Psychiatrica Scandinavica is cited in as a pioneering study in the Journal of National Cancer Institute, July 3, 2012:

Meta-Analysis of Efficacy of Interventions for Elevated Depressive Symptoms in Adults Diagnosed With Cancer
Stacey L. Hart, Michael A. Hoyt, Michael Diefenbach, Derek R. Anderson, Kristin M. Kilbourn, Lynette L. Craft, Jennifer L. Steel,
Pim Cuijpers, David C. Mohr, Mark Berendsen, Bonnie Spring, Annette L. Stanton
Manuscript received June 28, 2011; revised April 30, 2012; accepted May 04, 2012.
Correspondence to: Annette L. Stanton, PhD, Department of Psychology, 1285 Franz Hall, Box 951563, University of California Los Angeles, Los Angeles